Which statement best describes non-beta-lactam PG inhibitors?

Which statement best describes non-beta-lactam PG inhibitors?

• A. They inactivate beta-lactamases
• B. They are all broad-spectrum
• C. They have no risk of resistance
• D. An example is Vancomycin, a glycopeptide that inhibits alanine-alanine crossbridges

Answer: (D)

Non-beta-lactam inhibitors of peptidoglycan synthesis are antibiotics that block building the bacterial cell wall without targeting PBPs or using beta-lactam chemistry. An example is vancomycin, a glycopeptide that binds to the D-Ala-D-Ala terminus of peptidoglycan precursors. By grabbing that terminal dipeptide, it prevents the addition of new subunits and stops the crosslinking step needed to strengthen the wall. This direct interaction with the growing cell wall explains why vancomycin is effective against many Gram-positive bacteria, while not typically active against Gram-negative ones due to outer-m membrane barriers. This concept helps distinguish why the other statements don’t fit. Inhibiting beta-lactamases is the role of beta-lactamase inhibitors, not non-beta-lactam PG inhibitors. Not all non-beta-lactam PG inhibitors are broad-spectrum—vancomycin, for example, mainly targets Gram-positives. And resistance can arise to these agents just like any antibiotic, so there is always some risk of resistance.

Non-beta-lactam inhibitors of peptidoglycan synthesis are antibiotics that block building the bacterial cell wall without targeting PBPs or using beta-lactam chemistry. An example is vancomycin, a glycopeptide that binds to the D-Ala-D-Ala terminus of peptidoglycan precursors. By grabbing that terminal dipeptide, it prevents the addition of new subunits and stops the crosslinking step needed to strengthen the wall. This direct interaction with the growing cell wall explains why vancomycin is effective against many Gram-positive bacteria, while not typically active against Gram-negative ones due to outer-m membrane barriers.

This concept helps distinguish why the other statements don’t fit. Inhibiting beta-lactamases is the role of beta-lactamase inhibitors, not non-beta-lactam PG inhibitors. Not all non-beta-lactam PG inhibitors are broad-spectrum—vancomycin, for example, mainly targets Gram-positives. And resistance can arise to these agents just like any antibiotic, so there is always some risk of resistance.